Physician profile
Keith E Sadel
NPI 1104939495
$13,120.05
in general payments reported to CMS, 2019-2025
62 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $1,897 · 2021: $2,186 · 2022: $2,320 · 2023: $1,684 · 2024: $1,904 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,822.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,347.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,340.06 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,169.53 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $950.49 | 2019-2025 | Vraylar, Ubrelvy, Viberzi |
| Amgen INC. | $907.17 | 2019-2025 | Otezla, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $709.91 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $651.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $511.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $498.21 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $420.27 | 2019-2025 | Spravato |
| Kowa Pharmaceuticals America, INC. | $364.15 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.43 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $307.08 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $287.91 | 2019-2022 | |
| Esperion Therapeutics, INC. | $244.86 | 2021-2025 | Nexletol |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Sadel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.